Walaphage G 2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing insulin sensitivity, and promoting peripheral glucose uptake and utilization. This dual mechanism addresses both insulin deficiency and insulin resistance, making Walaphage G 2 Tablet PR effective in achieving optimal blood glucose levels in patients inadequately controlled by diet and exercise alone. The extended-release formulation ensures a sustained therapeutic effect, improving patient compliance and minimizing gastrointestinal side effects commonly associated with Metformin. It is recommended to administer the tablet with meals to further reduce gastrointestinal discomfort. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia, as these may increase the risk of lactic acidosis or hypoglycemia. Regular monitoring of blood glucose, renal function, and liver enzymes is essential during therapy. Walaphage G 2 Tablet PR should be used as part of a comprehensive diabetes management plan, including diet, exercise, and lifestyle modifications.